Tag: Survival

Improvements seen in overall survival, progression-free survival, and cancer-specific survival

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration

Lower odds of receiving key components of quality care seen for those with high overall social vulnerability index

Adherence to American Cancer Society guidelines linked to lower mortality in nonsmoking survivors of obesity-related cancer

Most patients who died after withdrawal of life-sustaining therapy were considered to have recovery potential of at least 1 percent

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion

Physical activity attenuates survival disparity between patients with stage III colon cancer and matched population controls

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab

Relative decline seen in cancer mortality among Blacks, but they still have higher mortality rates than Whites

Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6